Posted by AGORACOM
at 8:32 AM on Monday, February 22nd, 2021
Expedited formation of commercial team to launch its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system
Expects medical device manufacturer approval by the end of February
European regulatory approval as a commercial in vitro diagnostic device by early March.
XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) (“XPhyto” or the “Company“), is pleased to announce that the Company has expedited the formation of an experienced commercial team to launch its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system (“Covid-ID Lab”). Covid-ID Lab was developed by XPhyto’s exclusive German diagnostics development partner, 3a-diagnostics GmbH (“3a”). XPhyto expects 3a to receive ISO 13485 medical device manufacturer approval by the end of February and European regulatory approval as a commercial in vitro diagnostic device (CE-IVD) for Covid-ID Lab by early March.
The market launch team consists of world-class clinical and pharmaceutical executives and service providers who bring the experience and expertise necessary to effectively and rapidly drive the commercialization of Covid-ID Lab. Collectively, the team brings decades of experience in the biotech and pharmaceutical industries, including: executive leadership, business development, regulatory compliance, product launch, international marketing and sales, production, quality assurance, and M&A. In particular, members of the team have led medical diagnostic company growth from inception to over 500 million Euro per year in multinational sales.
“We are extremely fortunate to now have a team with deep expertise in medical diagnostic product commercialization. The team has extensive experience from regulatory approval to international production and sales,” said Hugh Rogers, CEO and Director of XPhyto. “As we near expected regulatory approval, XPhyto’s business is rapidly evolving from innovation to impact. We are working hard to put the Company in the best possible position to execute on our business strategy.”
Posted by AGORACOM-JC
at 7:17 PM on Sunday, February 21st, 2021
ORTHO Regenerative Technologies is a cutting-edge med tech firm that uses its proprietary RESTORE technology platform to dramatically improve the success rate of orthopedic and sports medicine surgeries.
In layman’s terms, that means company has a wonder delivery platform that delivers biologics – drugs made from biological processes – to repair soft tissues in the human body.
The technology uses biologics derived from things like plasma and bone marrow concentrate to regenerate new tissue in various musculoskeletal conditions.
This includes Wound Healing, Cartilage repair and Osteo-arthritis
So, how big is the market opportunity for Soft Tissue Repair? At least $5bn in the U.S. alone. This includes:
Rotator Cuff TEAR (which leads to shoulder dysfunction and pain):
4m patients in the U.S. alone
600,000 annual surgeries in the U.S. alone
$600m+ market opportunity
Meniscus Tear Repair (which is painful and compromises knee function):
There are 1.2m surgeries annually in U.S. alone
$1bn+ market opportunity
Cartilage Lesions Repair (this is where lesions cause friction and pain):
1.2m detected lesions annually in U.S. alone
120,000 surgeries and a lack of options
$1bn+ market opportunity
Get comfy for this insightful interview with Claude LeDuc, Ortho’s CEO.
Agoracom interviewed our Chief Medical Officer about our latest expansions, the striking results from treatments, and what it takes to build infrastructure for psychedelic-assisted healthcare.
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit www.novamind.ca
Posted by AGORACOM-JC
at 6:04 PM on Thursday, February 18th, 2021
As the name implies “PropTech” is a combination of two words and stands for “property technology.” As simple as that is, the implementation and importance of PropTech is anything but, which is why many companies are trying to capitalize on the rapidly growing paradigm shift, while Universal PropTech (UPI:TSXV) is actually delivering healthy building solutions developers, owners and operators across Canada.
More than just lip service, UPI clients include:
· Federal Government facilities for over 40 years
· Manulife
· Brookfield
· Billy Bishop Airport
· University of Toronto
· …. and many more
As a result, UPI has generated $35,000,000+ in revenue over the past 3 year – a number most small cap companies would be very happy with. But newly appointed Chief Growth Officer, Frank Carnevale sees a much bigger opportunity by winning exclusive licenses and partnerships with providers of great products that can significantly grow company revenues … and he has delivered pretty strongly against this mission statement in 2021.
BUT TODAY HE TOOK A GIANT LEAP FORWARD
The press release headline says it all:
Universal PropTech Inc. Invests in and Secures defined Agency Rights for ISBRG Corp.’s SpotLight-19(C) Technology Designed to Detect Covid-19 Non-Invasively in Under One Minute
In short, this technology takes a non-invasive scan of a person’s finger with a harmless beam of light designed to provide confirmation of Covid-19 infection in less than 1 minute.
How significant is this announcement and what does it mean to the Company’s growth?
Watch our interview with CGO Carnevale to learn all about it.
Posted by AGORACOM
at 3:56 PM on Thursday, February 18th, 2021
Harborside Inc. (“Harborside”, or the “Company) (CSE: HBOR), (OTCQX: HBORF), a California-focused, vertically-integrated cannabis enterprise, is pleased to announce that it has closed its previously announced upsized brokered private placement of units of the Company at a price of C$2.55 per SVS Unit (as defined below) and C$255.00 per MVS Unit (as defined below) for aggregate gross proceeds of C$35,103,045 (the “Offering”). Beacon Securities Limited and ATB Capital Markets acted as co-lead agents in connection with the Offering (the “Agents”).
“We are very pleased with the strong investor interest and demand we received during our recent upsized offering,” said Peter Bilodeau, Interim CEO of Harborside. “With a strengthened balance sheet, Harborside is well positioned to further accelerate our growth as we enter 2021. We remain focused on continuing to build scale in the California market by optimizing and generating further efficiencies at our Salinas farm while continuing to provide best-in-class retail experiences and the high-quality cannabis products our customers in California have come to expect from Harborside.”
Each unit issued to non-residents of the United States (an “SVS Unit”) is comprised of one subordinate voting share of the Company (a “Subordinate Voting Share”) and one Subordinate Voting Share purchase warrant (a “Warrant”) of the Company. Each Warrant underlying an SVS Unit is exercisable to acquire one Subordinate Voting Share of the Company for a period of 36 months following closing of the Offering (the “Closing”) at an exercise price of C$3.69 per Subordinate Voting Share, subject to adjustment and acceleration in certain events. A total of 5,806,700 SVS Units were issued pursuant to the Offering.
All investors that are considered residents of the United States under the United States Securities Exchange Act of 1934 were issued units (each, an “MVS Unit”) comprised of multiple voting shares of the Company (the “Multiple Voting Shares”) and Multiple Voting Share purchase warrants of the Company, based on the same economic equivalency of each Multiple Voting Share converting into 100 Subordinate Voting Shares. The Multiple Voting Shares are intended to minimize the proportion of the outstanding voting securities of the Company that are held by residents of the United States for purposes of determining whether the Company is a “foreign private issuer”. The holders of Multiple Voting Shares are entitled to one vote in respect of each Subordinate Voting Share into which such Multiple Voting Share could be converted, and as such the Multiple Voting Shares do not necessarily hold voting rights that are superior to the holders of Subordinate Voting Shares, on an as converted to Subordinate Voting Shares basis. A total of 79,592 MVS Units were issued pursuant to the Offering.
In consideration for their services, the Company paid the Agents a cash commission equal to C$1,451,340.75 and issued the Agents an aggregate of 569,154 broker warrants (“Broker Warrants”). Each Broker Warrant is exercisable to acquire, within 12 months from Closing, one SVS Unit at an exercise price of C$2.55 per SVS Unit.
Posted by AGORACOM
at 11:58 AM on Thursday, February 18th, 2021
Deepest borehole at Adumbi intersects 55.43 metres grading 2.76 g/t Au including 12.45 metres grading 8.11 g/t Au
Significant widths and grades will increase the current inferred mineral resource of 2.19 million ounces (28.97 million tonnes grading 2.35 g/t gold) at Adumbi
Loncor Resources Inc. (“Loncor” or the “Company“) (TSX: “LN”; OTCQX: “LONCF”; FSE: “LO51”) is pleased to announce further significant assay results from its drilling program within its 84.68% owned Imbo Project in the eastern part of the Ngayu greenstone belt in the Democratic Republic of the Congo. The deepest borehole drilled to date at its flagship Adumbi deposit, LADD007 intersected 55.43 metres grading 2.76 g/t gold (including 12.45 metres grading 8.11 g/t Au). Assay results were also received for core hole LADD006, which was a shallower hole drilled on the northeastern contact of the Adumbi deposit, with expected grades and widths.
Mineralized sections for boreholes LADD007 and LADD006 are summarised in the table below:
Borehole Number
From (m)
To (m)
Intersected Width (m)
Grade (g/t) Au
LADD007
99.95
107.80
7.85
1.45
LADD007
540.62
596.05
55.43
2.76
LADD007 including
583.60
596.05
12.45
8.11
LADD007
607.90
611.27
3.37
4.61
LADD006
299.37
302.25
2.88
2.64
LADD006
308.00
309.00
1.00
21.20
LADD006
322.10
337.30
15.20
1.67
LADD006
353.35
357.85
4.50
3.25
Borehole LADD007 had an inclination of minus 68 degrees and azimuth of 218 degrees at the start of hole and regular measurements of inclination and azimuth were taken at 30 metre intervals down the hole. All core was orientated, and it is estimated that the true widths of the mineralised sections are approximately 89% of the intersected width. All intercepted grades are uncut. Borehole LADD007 intersected the mineralization at a depth of 100 metres below S52 and approximately 40 metres below the open pit (see Figures 2 and 3 below). Borehole LADD006 had an inclination of minus 58 degrees and azimuth of 218 degrees and it is estimated that the true widths of the mineralised sections of LADD006 are approximately 95% of the intersected width.
Commenting on these latest drilling results, Loncor President Peter Cowley said: “We continue to be encouraged by the results at Adumbi. Results from all five boreholes of our current drilling program have intersected significant widths and grades and will increase the current inferred mineral resource of 2.19 million ounces (28.97 million tonnes grading 2.35 g/t gold) at Adumbi. We are especially pleased with the continuity of gold mineralization at depth as highlighted in Figures 2 and 3.”
Posted by AGORACOM
at 8:58 AM on Thursday, February 18th, 2021
3,400m drilled on the Trove Property over 12 holes.
Encountered mineralization 200 meters below surface and at 300m
Durango drilled three scout holes on the East Barry Property totaling 1,969 meters
2,000 samples are pending assay results at multiple labs for both the Trove and East Barry properties.
Durango Resources Inc.(TSXV:DGO) (Frankfurt-86A1) (OTC:ATOXF), (the “Company” or “Durango”) announces that the drilling campaign on its wholly owned Trove and East Barry Properties at Windfall Lake is still underway.
Trove Property
Currently, Durango is drilling holes on the northern portion of the Trove Property which was inaccessible until late 2020 due to late cold weather conditions. Approximately 3,400 meters has been drilled on the Trove Property in 2020 and 2021 over 12 holes. The Trove exploration program was designed to test the high priority Induced Polarization (“IP”) anomalies in the northern section of the Trove Property. So far, the majority of the mineralized sections were encountered within 200 meters below surface, with some exceptions encountering mineralization at depths of 300m and more.
East Barry Property
In January, Durango drilled three scout holes on the East Barry Property totaling 1,969 meters to try to determine the location of the felsic dykes in intrusive pluton. The scout holes enabled Durango to derive structural and lithological data on the East Barry and to test till anomaly targets which were previously inaccessible.
More than 2,000 samples are pending assay results at multiple labs for both the Trove and East Barry properties. Durango has encountered further lab delays due to a Covid-19 breakout at one of the processing facilities earlier this month, so the Company has secured additional labs to help alleviate the turnaround time and assay delays. Durango’s exploration and drill teams have not been exposed and continue to remain safe and healthy at the camp.
Posted by AGORACOM-JC
at 4:11 PM on Wednesday, February 17th, 2021
The global behavioural health market size is expected to reach approximately US$ 245 billion by 2027 and estimated to grow at CAGR of 2.5 % over the forecast time frame 2020 to 2027.
As a consequence of the increasing incidence of mental health disorders, global demand for mental health facilities is increasing.
Psychedelics are going to go through parabolic, paradigm-shifting growth because of their ability to treat anxiety and depression amongst other things
Novamind is a leading mental health company specialized in psychedelic medicine, building the infrastructure required for a regulated psychedelics industry.
Highlights:
Rapidly expanding a network of outpatient mental health clinics and research sites
4 clinics in Utah, 1 more anticipated this quarter
Provides ketamine-assisted psychotherapy and Spravato™ (esketamine) treatments;
Ketamine treatment volume grew 90% from 2019 to 2020
During the same period, total Spravato™ treatments rose 400%
Positioned to facilitate MDMA and psilocybin therapy post-FDA approval
Building centers of excellence for future approved psychedelic treatments
Approximately CAN$1,900,000 in 2019 revenue
Strong insider ownership (32.3%)
Watch this powerful interview with Dr. Reid Robison, Chief Medical Officer and Director of Novamind.
